STOCK TITAN

Cartesian Therapeutics Inc - RNAC STOCK NEWS

Welcome to our dedicated news page for Cartesian Therapeutics (Ticker: RNAC), a resource for investors and traders seeking the latest updates and insights on Cartesian Therapeutics.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Cartesian Therapeutics's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Cartesian Therapeutics's position in the market.

Rhea-AI Summary
Cartesian Therapeutics, Inc. (RNAC) to present at the 23rd Annual Needham Virtual Healthcare Conference on April 9, 2024, discussing mRNA cell therapy for autoimmune diseases.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.44%
Tags
conferences
-
Rhea-AI Summary
Cartesian Therapeutics, Inc. (RNAC) grants inducement awards to four new employees, offering them options to purchase shares of the company's common stock. The options amount to 765,000 shares with an exercise price of $0.5601 per share, vesting over a four-year period.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.44%
Tags
none
-
Rhea-AI Summary
Cartesian Therapeutics, Inc. (NASDAQ: RNAC) announced stockholder approval for the conversion of Series A Non-Voting Convertible Preferred Stock into common stock and a 1-for-30 reverse stock split. The reverse stock split will reduce outstanding shares from 165.5 million to 5.5 million, maintaining trading under the symbol 'RNAC'.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-13.83%
Tags
Rhea-AI Summary
Cartesian Therapeutics, Inc. (RNAC) reports positive Phase 2b study data for Descartes-08 mRNA CAR-T therapy in myasthenia gravis (MG). The Company plans to initiate Phase 2 studies in systemic lupus erythematosus (SLE) and other autoimmune indications. Recent IND clearance for Descartes-15 for multiple myeloma. Financially, the company holds approximately $118.3M in cash, supporting operations until the second half of 2026.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-8.04%
Tags
-
Rhea-AI Summary
Cartesian Therapeutics, Inc. (RNAC) to present at two investor conferences in March 2024, showcasing mRNA cell therapy for autoimmune diseases.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.12%
Tags
conferences
-
Rhea-AI Summary
Cartesian Therapeutics, Inc. (RNAC) granted an inducement award to a new employee, offering 375,000 shares at $0.69 per share. The option vests over four years, fully by 2028, under Nasdaq Listing Rules. The award aims to attract and retain talent.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.13%
Tags
none
Rhea-AI Summary
Cartesian Therapeutics, Inc. (RNAC) plans to transition its corporate headquarters to Frederick, Maryland, to support expanded cGMP manufacturing of mRNA cell therapies for autoimmune diseases. The new 20,000 square foot facility will enable the company to scale its manufacturing capabilities for late-stage clinical and commercial supply while maintaining product quality.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.13%
Tags
none
-
Rhea-AI Summary
Cartesian Therapeutics, Inc. announced the granting of inducement awards to five new employees, issuing them options to purchase shares of the company's common stock. The options have a per share exercise price of $0.75 and are exercisable for an aggregate of 708,546 shares. Each option vests over time and has a ten-year term. The options were granted under Nasdaq Listing Rules as inducements material to each employee's entry into employment with the Company.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
5.29%
Tags
none
-
Rhea-AI Summary
Cartesian Therapeutics, a clinical-stage biotechnology company (NASDAQ: RNAC), highlighted its recent progress and outlined 2024 strategic priorities across its pipeline of mRNA cell therapy product candidates. The company reported positive 12-month follow-up data from Phase 2a study of Descartes-08 in myasthenia gravis, with durable depletion of autoantibodies and clinically meaningful improvements in MG severity scores. The company also announced the expansion of its clinical pipeline following recent IND clearance for Descartes-15, a next-generation mRNA CAR-T product candidate. Cartesian ended 2023 with approximately $118M pro forma cash and cash equivalents, expected to support planned operations into the second half of 2026.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
5.94%
Tags
none
Rhea-AI Summary
Cartesian Therapeutics, Inc. (NASDAQ: RNAC) announced positive twelve-month follow-up data from its Phase 2a trial of Descartes-08 in patients with generalized myasthenia gravis (MG), a chronic autoimmune disorder. Descartes-08, an autologous anti-B-cell maturation antigen (BCMA) mRNA CAR-T, showed durable depletion of autoantibodies and clinically meaningful improvements in MG severity scores without the need for lymphodepleting chemotherapy. The manuscript titled, 'Twelve-Month Follow-Up of Patients With Generalized Myasthenia Gravis Receiving BCMA-Directed mRNA Cell Therapy,' has been submitted for peer-review and can be accessed on the online preprint server, medRxiv. Topline data from a Phase 2b placebo-controlled study is expected in mid-2024.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
5.94%
Tags
Cartesian Therapeutics Inc

Nasdaq:RNAC

RNAC Rankings

RNAC Stock Data

344.75M
1.09M
40.11%
12.34%
5.31%
Pharmaceutical Preparation Manufacturing
Manufacturing
Link
US
Watertown

About RNAC

selecta biosciences, inc. is a clinical-stage biopharmaceutical company that is focused on unlocking the full potential of biologic therapies by mitigating unwanted immune responses. selecta plans to combine its tolerogenic synthetic vaccine particles (svp™) to a range of biologics for rare and serious diseases that require new treatment options. the company’s current proprietary pipeline includes svp-enabled enzyme, oncology and gene therapies. sel-212, the company’s lead candidate in phase 2, is being developed to treat severe gout patients and resolve their debilitating symptoms, including flares and gouty arthritis. selecta’s sel-403 product candidate, a combination therapy consisting of svp-rapamycin and lmb-100, recently entered a phase 1 trial in 2018 for the treatment of patients with malignant pleural or peritoneal mesothelioma. selecta’s proprietary gene therapy product candidates are being developed for rare inborn errors of metabolism and have the potential to enable repeat